Graves' Disease Market Research Report present a detailed analysis of the market listing Graves' Disease Epidemiology, Drug therapies and pipeline for study period from 2016-2027.

Graves' Disease Market Size & Share | Graves' Disease Market Research Report, Market Analysis, Market Growth, trends and Forecast

DelveInsight's 'Graves' Disease - Market Insights, Epidemiology and Market Forecast-2028' report delivers an in-depth understanding of the disease, historical &amp; forecasted epidemiology as well as the market trends of Graves' Disease in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Graves' Disease (GD) from 2017 to 2028 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market. <h2>Geography Covered</h2>• The United States• EU5 (Germany, France, Italy, Spain and the United Kingdom)• Japan <h2>Study Period: 2017-2028</h2> <h2>Graves' Disease - Disease Understanding</h2>Graves' disease is an autoimmune disorder that causes hyperthyroidism or overactive thyroid. With this disease, the immune system attacks the thyroid and causes it to make more thyroid hormone than the body needs. The thyroid is a small, butterfly-shaped gland in the front of your neck. Thyroid hormones control how the body uses energy, so they affect nearly every organ in your body—even the way heartbeats. If left untreated, hyperthyroidism can cause serious problems with the heart, bones, muscles, menstrual cycle, and fertility. During pregnancy, untreated hyperthyroidism can lead to health problems for the mother and baby. Graves' disease also can affect the eyes and skin.Graves' disease is an autoimmune disorder that causes hyperthyroidism or overactive thyroid. With this disease, the immune system attacks the thyroid and causes it to make more thyroid hormone than the body needs. The thyroid is a small, butterfly-shaped gland in the front of your neck. Thyroid hormones control how the body uses energy, so they affect nearly every organ in your body—even the way heartbeats. If left untreated, hyperthyroidism can cause serious problems with the heart, bones, muscles, menstrual cycle, and fertility. During pregnancy, untreated hyperthyroidism can lead to health problems for the mother and baby. Graves' disease also can affect the eyes and skin.The DelveInsight Graves' Disease (GD) market report gives a thorough understanding of the Graves' Disease by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Graves' Disease in the US, Europe, and Japan. <h2>Graves' Disease Epidemiology</h2>The Graves' Disease (GD) epidemiology division provides the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed and treatable patient pool and their trends along with assumptions undertaken.The disease epidemiology covered in the report is segmented by total incident population, diagnosed incident population, age-specific incident population, gender-specific incident population and by Clinical Manifestations of Graves' disease.The DelveInsight report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.According to DelveInsight, the incident population of Graves' Disease was estimated to be 384,538 [7MM] in 2018. United States accounts for the highest Graves' Disease cases, followed by EU5 (Germany, France, Italy, Spain &amp; UK) and Japan. Among the EU5 countries Germany had the highest incident patient population of Graves' Disease, followed by France with an incident population of 33,365 in 2018. <h2>Graves' Disease Management</h2>This segment of the Graves' Disease report encloses the key-cross analysis of marketed drugs.Currently, there is no cure for Graves' disease. The goals of treatment of Graves' disease are to control symptoms efficiently and restore euthyroidism. The three options for treating patients with hyperthyroidism are anti-thyroid drugs (Tapazole (Methimazole), Carbimazole and Propylthiouracil) radioactive iodine ablation, and surgery. All three therapeutic options would be effective in the treatment of patients with Graves' disease, whereas patients with toxic adenoma or toxic multinodular goiter should have either radioactive iodine therapy or surgery since these patients rarely go into remission. In patients with toxic nodular goiter, ATDs are generally used to restore euthyroidism before definitive treatment with surgery or radioactive iodine and infrequently used as a long-term treatment when the other two therapies are contraindicated, or the patient has a short life expectancy. If drugs were used as the primary therapy, it should be given for at least 12-18 months. In case of surgery is chosen for primary therapy, near total or total thyroidectomy is the choice of surgery. RAI therapy can be done if there are side effects of the anti-thyroid drugs, history of neck surgery or external neck radiation. Beta-blocker can be used to reduce signs and symptoms of thyrotoxicosis and to inhibit the conversion of T4 to T3 in the peripheral organs. <h2>Graves' Disease Market Outlook</h2>The Graves' Disease (GD) market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.Antithyroid drugs are the most recommended treatment of Graves' Disease. Methimazole is the utmost prescribed antithyroid drug in the US, Japan, Germany, France, Italy and Spain, however, Carbimazole is preferred by the UK doctors. Radioactive Iodine method has gained its importance in last few years with low dose requirement and comparatively low relapse rate. Thyroid surgery is mostly recommended in complicated cases were RAI and antithyroid drugs are not a choice.According to DelveInsight, the global market of Graves' Disease (GD) was estimated to be USD 306.3 million in 2018. The United States accounts for the largest market size of Graves' Disease, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain), and Japan. Among the EU5 countries, Germany had the highest market size with 27.1 million in 2018, while Spain had the lowest market size of Graves' Disease (GD). The increasing awareness of the disease assisted by organizational support along with the promising pipeline therapies is expected to fuel the market size during the forecasted period of 2019-2028.<h2>Graves' Disease Drugs Uptake</h2>This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.The entry of novel drug CFZ533, Novartis by 2024 may drive the otherwise stringent therapeutic market of the Grave's Disease.&nbsp;<h2>Graves' Disease Report Insights</h2>• Patient Population• Therapeutic Approaches• Pipeline Analysis• Market Size and Trends• Market Opportunities• Impact of upcoming Therapies <h2>Graves' Disease Report Key Strengths</h2>• 10 Year Forecast• 7MM Coverage• Epidemiology Segmentation• Drugs Uptake• Highly Analyzed Market• Key Cross Competition <h2>Graves' Disease Report Assessment</h2>• Current Treatment Practices• Unmet Needs• Detailed Pipeline Product Profiles• Market Attractiveness• Market Drivers and Barriers <h2>Key Benefits</h2>• This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving the Graves' Disease market.• Organize sales and marketing efforts by identifying the best opportunities for Graves' Disease market.• To understand the future market competition in the Graves' Disease market.

1 Key Insights2 Graves' disease Market Overview at a Glance2.1 Market Share (%) Distribution of Graves' disease in 20172.2 Market Share (%) Distribution of Graves' disease in 20283 Disease Overview: Graves' Disease3.1 Introduction3.2 Causes and Symptoms of Graves' disease3.3 Clinical Manifestations of Graves' disease3.4 Pathophysiology of Graves' disease3.5 Pathophysiology of Graves' Ophthalmopathy3.6 Genetic Basis of Graves' Disease3.7 Diagnosis3.7.1 Diagnostic Criteria for Thyroid Storm (TS) of the Japan Thyroid Association3.7.2 The Burch-Wartofsky Point Scale for Diagnosis of Thyroid Storm3.7.3 Diagnosis and Differential Diagnosis of Thyroid Dermopathy3.7.4 Japan Thyroid Association: Guidelines for the Diagnosis of Graves 'disease3.8 Sensitive Biomarkers of Graves' disease3.9 Risk Factors and Complications4 Epidemiology and Patient Population4.1 Key Findings4.2 7MM Total Incident Patient Population of GD5 Country Wise-Epidemiology of GD5.1 United States5.1.1 Assumptions and Rationale5.1.2 Total Incident cases of Graves' disease in the US5.1.3 Gender Specific Incident cases of Graves' disease in the US5.1.4 Age Specific Incident cases of Graves' disease in the US5.1.5 Diagnosed Incident Cases of Graves' disease in the US5.1.6 Clinical Manifestations of Graves' disease in the US5.2 EU55.2.1 Assumptions and Rationale5.2.2 Germany5.2.2.1 Total Incident cases of Graves' disease in Germany5.2.2.2 Gender Specific Incident cases of Graves' disease in Germany5.2.2.3 Age Specific Incident cases of Graves' disease in Germany5.2.2.4 Diagnosed Incident Cases of Graves' disease in Germany5.2.2.5 Clinical Manifestations of Graves' disease in Germany5.2.3 France5.2.3.1 Total Incident cases of Graves' disease in France5.2.3.2 Gender Specific Incident cases of Graves' disease in France5.2.3.3 Age Specific Incident cases of Graves' disease in France5.2.3.4 Diagnosed Incident Cases of Graves' disease in France5.2.3.5 Clinical Manifestations of Graves' disease in France5.2.4 Italy5.2.4.1 Total Incident cases of Graves' disease in Italy5.2.4.2 Gender Specific Incident cases of Graves' disease in Italy5.2.4.3 Age Specific Incident cases of Graves' disease in Italy5.2.4.4 Diagnosed Incident Cases of Graves' disease in Italy5.2.4.5 Clinical Manifestations of Graves' disease in Italy5.2.5 Spain5.2.5.1 Total Incident cases of Graves' disease in Spain5.2.5.2 Gender Specific Incident cases of Graves' disease in Spain5.2.5.3 Age Specific Incident cases of Graves' disease in Spain5.2.5.4 Diagnosed Incident Cases of Graves' disease in Spain5.2.5.5 Clinical Manifestations of Graves' disease in Spain5.2.6 United Kingdom5.2.6.1 Total Incident cases of Graves' disease in the UK5.2.6.2 Gender Specific Incident cases of Graves' disease in the UK5.2.6.3 Age-Specific Incident cases of Graves' disease in the UK5.2.6.4 Diagnosed Incident Cases of Graves' disease in the UK5.2.6.5 Clinical Manifestations of Graves' disease in the UK5.3 Japan5.3.1 Assumptions and Rationale5.3.2 Total Incident cases of Graves' disease in Japan5.3.3 Gender Specific Incident cases of Graves' disease in Japan5.3.4 Age Specific Incident cases of Graves' disease in Japan5.3.5 Diagnosed Incident Cases of Graves' disease in Japan5.3.6 Clinical Manifestations of Graves' disease in Japan6 Current Treatment Practices7 Practice Guidelines for Graves' disease7.1 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis7.2 2018 European Thyroid Association Guideline for the Management of Graves' Hyperthyroidism7.3 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy7.4 2016 Guidelines for the management of thyroid storm from The Japan Thyroid Association and Japan Endocrine Society8 Unmet Needs9 Marketed Drugs9.1 Key Cross of Marketed Drugs10 Emerging Therapies10.1 Key Cross of Emerging Therapies10.2 CFZ 533: Novartis10.2.1 Product Description10.2.2 Clinical Development10.2.2.1 Clinical Trials Information10.2.3 Advantages and Disadvantages10.2.4 Safety and Efficacy10.2.5 Product Profile11 Graves' disease: 7 Major Market Analysis11.1 Key Findings11.2 Market Size of GD in 7MM12 Market Outlook by Country13 The United States: Market Outlook13.1 United States Market Size13.1.1 Total Market size of GD13.1.2 GD Market by Therapies14 EU-5 Countries: Market Outlook14.1 Germany Market Size14.1.1 Total Market size of GD14.1.2 GD Market by Therapies14.2 France Market Size14.2.1 Total Market size of GD14.2.2 GD Market by Therapies14.3 Italy Market Size14.3.1 Total Market size of GD14.3.2 GD Market by Therapies14.4 United Kingdom Market Size14.4.1 Total Market size of GD14.4.2 GD Market by Therapies14.5 Spain Market Size14.5.1 Total Market size of GD14.5.2 GD Market by Therapies15 Japan: Market Outlook15.1 Japan Market Size15.1.1 Total Market size of GD15.1.2 GD Market by Therapies16 Market Drivers17 Market Barriers18 Appendix18.1 Report Methodology19 DelveInsight Capabilities20 Disclaimer21 About DelveInsight

Graves' Disease - Market Insights, Epidemiology and Market Forecast-2028

DelveInsight's 'Graves' Disease- Market Insights, Epidemiology and Market Forecast-2028' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Graves' Disease in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan. 